Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:1884

Eurocine Vaccines AB (EUCI) - Financial and Strategic SWOT Analysis Review

Eurocine Vaccines AB (EUCI) - Financial and Strategic SWOT Analysis Review

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $125.00
Meta Description Eurocine Vaccines AB (Eurocine) is a publicly listed, clinical stage development company. The company develops patent protected nasal vaccines against influenza, pneumococci and HIV. Eurocine licenses its patent protected vaccine products to international
Publisher GlobalData
Date of Report Dec 3, 2013
Quick Overview
Summary

Eurocine Vaccines AB (Eurocine) is a publicly listed, clinical stage development company. The company develops patent protected nasal vaccines against influenza, pneumococci and HIV. Eurocine licenses its patent protected vaccine products to international development and marketing partners in consideration for milestone payments and royalties. Eurocine’s technology enables efficient and gentle vaccination through the nose by means of endogenous additives. The company conducts its immunological preclinical development by outsourcing to scientists and research groups in Karolinska institute and the Swedish institute for infectious disease control.

Eurocine Vaccines AB Key Recent Developments

Sep 24, 2012: Eurocine Vaccines Appoints Anna-Karin Maltais As Chief Scientific OfficernMay 25, 2012: Eurocine Announces Positive Data From Experimental Nasal Pneumococcal Vaccine Program
Feb 10, 2012: Eurocine Vaccines Reports Q2 Fiscal 2012 ResultsGDPH82491FSA

This comprehensive SWOT profile of Eurocine Vaccines AB provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Eurocine Vaccines AB - Key Facts 5
Eurocine Vaccines AB - Key Employees 6
Eurocine Vaccines AB - Key Employee Biographies 7
Eurocine Vaccines AB - Major Products and Services 8
Eurocine Vaccines AB - Pharmaceutical Pipeline Products Data 9
Eurocine Vaccines AB, Pipeline Products by Therapy Area 9
Eurocine Vaccines AB, Pipeline Products by Development Phase 10
Eurocine Vaccines AB - History 12
Eurocine Vaccines AB - Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
Eurocine Vaccines AB - Business Description 14
Eurocine Vaccines AB - Corporate Strategy 15
Eurocine Vaccines AB - SWOT Analysis 16
SWOT Analysis - Overview 16
Eurocine Vaccines AB - Strengths 16
Strength - Ongoing Research Projects 16
Strength - Proprietary Adjuvant Systems 16
Strength - Partnerships and Collaborations 16
Eurocine Vaccines AB - Weaknesses 17
Weakness - Declining Efficiency Indicators 17
Eurocine Vaccines AB - Opportunities 17
Opportunity - Key Business Initiatives 17
Opportunity - Market Prospects: Vaccines Market 17
Opportunity - Market Potential: HIV 17
Eurocine Vaccines AB - Threats 17
Threat - Uncertain R&D Outcomes 17
Threat - Competition and Technological Change 18
Threat - Government Regulations 18
Eurocine Vaccines AB - Key Competitors 19
Section 3 – Company Financial Ratios 20
Financial Ratios - Capital Market Ratios 20
Financial Ratios - Annual Ratios 20
Performance Chart 22
Financial Performance 22
Financial Ratios - Interim Ratios 23
Financial Ratios - Ratio Charts 24
Section 4 – Company’s Lifesciences Financial Deals and Alliances 25
Eurocine Vaccines AB, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 25
Eurocine Vaccines AB, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 26
Eurocine Vaccines AB, Recent Deals Summary 27
Section 5 – Company’s Recent Developments 28
Eurocine Vaccines AB, Recent Developments 28
Sep 24, 2012: Eurocine Vaccines Appoints Anna-Karin Maltais As Chief Scientific Officer 28
May 25, 2012: Eurocine Announces Positive Data From Experimental Nasal Pneumococcal Vaccine Program 28
Feb 10, 2012: Eurocine Vaccines Reports Q2 Fiscal 2012 Results 28
Section 6 – Appendix 29
Methodology 29
Ratio Definitions 29
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Eurocine Vaccines AB, Key Facts 5
Eurocine Vaccines AB, Key Employees 6
Eurocine Vaccines AB, Key Employee Biographies 7
Eurocine Vaccines AB, Major Products and Services 8
Eurocine Vaccines AB, Number of Pipeline Products by Therapy Area 9
Eurocine Vaccines AB, Number of Pipeline Products by Development Stage 10
Eurocine Vaccines AB, Pipeline Products By Therapy Area and Development Phase 11
Eurocine Vaccines AB, History 12
Eurocine Vaccines AB, Subsidiaries 13
Eurocine Vaccines AB, Key Competitors 19
Eurocine Vaccines AB, Ratios based on current share price 20
Eurocine Vaccines AB, Annual Ratios 20
Eurocine Vaccines AB, Interim Ratios 23
Eurocine Vaccines AB, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 25
Eurocine Vaccines AB, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 26
Eurocine Vaccines AB, Recent Deals Summary 27
Currency Codes 29
Capital Market Ratios 29
Equity Ratios 30
Profitability Ratios 30
Cost Ratios 31
Liquidity Ratios 31
Leverage Ratios 32
Efficiency Ratios 32

List of Figures
Eurocine Vaccines AB, Pipeline Products by Therapy Area 9
Eurocine Vaccines AB, Pipeline Products by Development Phase 10
Eurocine Vaccines AB, Performance Chart (2008 - 2012) 22
Eurocine Vaccines AB, Ratio Charts 24
Eurocine Vaccines AB, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 25
Eurocine Vaccines AB, Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013 26




...